<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04688736</url>
  </required_header>
  <id_info>
    <org_study_id>IHBDH-CTA202101</org_study_id>
    <nct_id>NCT04688736</nct_id>
  </id_info>
  <brief_title>Efficacy of Placebo Versus Chlorpheniramine for the Prevention of Allergic Transfusion Reactions.</brief_title>
  <official_title>A Prospective, Randomized, Double-blind Controlled Trial of Chlorpheniramine Pretransfusion Medication for Allergic Transfusion Reactions</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Institute of Hematology &amp; Blood Diseases Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Institute of Hematology &amp; Blood Diseases Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a prospective, randomized, double-blind controlled trial to evaluate the efficacy of&#xD;
      placebo versus chlorpheniramine for the prevention of allergic transfusion reactions.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">January 1, 2021</start_date>
  <completion_date type="Anticipated">December 31, 2022</completion_date>
  <primary_completion_date type="Anticipated">December 31, 2022</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
    <masking_description>Neither patients nor medical staff, including physicians and nurses participating in this study, will know the group assignment after allocation.</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>The rate of allergic-transfusion reactions</measure>
    <time_frame>within 4 hours from the start of the transfusion</time_frame>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">6642</enrollment>
  <condition>Allergic Transfusion Reaction</condition>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Each recruited subject will oral 8mg placebo 20 minutes before blood transfusion.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Chlorpheniramine</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Each recruited subject will oral 8mg chlorpheniramine 20 minutes before blood transfusion.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>The tablet resembles chlorpheniramine but has no therapeutic value.</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Chlorpheniramine</intervention_name>
    <description>An antihistamine that reduces the natural chemical histamine in the body.</description>
    <arm_group_label>Chlorpheniramine</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  18~65 years old.&#xD;
&#xD;
          -  Subject is diagnosed with hematological disorder and requires blood product (i.e.&#xD;
             suspended red blood cells, apheresis platelets, fresh frozen plasma) transfusions.&#xD;
&#xD;
          -  Subject can fully understand and voluntarily sign informed consent forms.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Subject with a history of allergic diseases.&#xD;
&#xD;
          -  Subject experienced at least 1 moderate/severe or 2 mild allergic reactions in the&#xD;
             past.&#xD;
&#xD;
          -  Subject received glucocorticoid or allergy drugs within 24 hours before blood&#xD;
             transfusion.&#xD;
&#xD;
          -  Subject transfused with washed RBC.&#xD;
&#xD;
          -  Received allo-HSCT transplantation before.&#xD;
&#xD;
          -  Subject with heart failure.&#xD;
&#xD;
          -  Subject suffered from sequelae of cardiovascular or cerebrovascular diseases.&#xD;
&#xD;
          -  Pregnant or nursing women.&#xD;
&#xD;
          -  Inability to understand or to follow study procedures.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <verification_date>December 2020</verification_date>
  <study_first_submitted>December 25, 2020</study_first_submitted>
  <study_first_submitted_qc>December 25, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">December 30, 2020</study_first_posted>
  <last_update_submitted>December 25, 2020</last_update_submitted>
  <last_update_submitted_qc>December 25, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">December 30, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Institute of Hematology &amp; Blood Diseases Hospital</investigator_affiliation>
    <investigator_full_name>Jun Shi</investigator_full_name>
    <investigator_title>Director of Regenerative Medicine Clinic Center</investigator_title>
  </responsible_party>
  <keyword>pretransfusion medication</keyword>
  <keyword>Chlorpheniramine</keyword>
  <keyword>blood transfusion</keyword>
  <keyword>allergic transfusion reaction</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Transfusion Reaction</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Chlorpheniramine</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

